^
BIOMARKER:

EGFR mutation

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
EGFR mutation
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
BPI-7711
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
C1
EGFR mutation
Non Small Cell Lung Cancer
afatinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
erlotinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
dacomitinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A2
EGFR mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive
:
A2
EGFR mutation
Non Small Cell Lung Cancer
bevacizumab + erlotinib
Sensitive
:
A2
EGFR mutation
Non Small Cell Lung Cancer
bevacizumab
Sensitive
:
A2
EGFR mutation
Non Small Cell Lung Cancer
erlotinib + ramucirumab
Sensitive
:
A2
EGFR mutation
Non Small Cell Lung Cancer
icotinib
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
afatinib
Sensitive
:
A2
EGFR mutation
Lung Adenocarcinoma
gefitinib
Sensitive
:
B
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
Tyrosine kinase inhibitor
Sensitive
:
B
EGFR mutation
Lung Cancer
EGFR inhibitor
Sensitive
:
B
EGFR mutation
Lung Adenocarcinoma
afatinib
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
U3-1402
Sensitive
:
B
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive
:
B
EGFR mutation
Lung Non-Small Cell Squamous Cancer
bevacizumab
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
gefitinib + rivoceranib
Sensitive
:
B
EGFR mutation
Solid Tumor
BDTX-189
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
nivolumab
Resistant
:
B
EGFR mutation
Non Small Cell Lung Cancer
rociletinib
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
ABCP
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive
:
B